Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone changes in early rheumatoid arthritis.

M J Green1, A A Deodhar

  • 1Rheumatology Research Unit, University of Leeds, Leeds, LS1 3EX, UK.

Best Practice & Research. Clinical Rheumatology
|May 19, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

A history of lameness is associated with reduced proportions of collagen type I relative to type III in the digital cushions of dairy cattle.

Journal of dairy science·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Longitudinal changes in neurocognitive functioning over two years in young people at increased genetic risk of bipolar disorder.

Journal of affective disorders·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same journal

The young adult with Juvenile Idiopathic Arthritis (JIA): A clinical review of transition, complications, and psychosocial management.

Best practice & research. Clinical rheumatology·2026
Same journal

Impact of fatigue on rheumatic diseases: Current perspectives.

Best practice & research. Clinical rheumatology·2026
Same journal

Pneumocystis prophylaxis in rheumatic disease.

Best practice & research. Clinical rheumatology·2026
Same journal

Cutaneous manifestations in myositis syndromes.

Best practice & research. Clinical rheumatology·2026
Same journal

Systemic sclerosis: A comprehensive systematic review of global epidemiology, sex and ethnic disparities, disease burden, and organ-specific involvement.

Best practice & research. Clinical rheumatology·2026
Same journal

Alopecia across the spectrum of rheumatic disease.

Best practice & research. Clinical rheumatology·2026
See all related articles

Rheumatoid arthritis causes bone loss through osteoprotegerin ligand, leading to disability. Early monitoring and anti-inflammatory treatments can slow bone loss, potentially preventing future functional decline.

Area of Science:

  • Rheumatology
  • Immunology
  • Orthopedics

Background:

  • Rheumatoid arthritis (RA) causes significant bone disease affecting the skeleton and leading to disability.
  • Pro-inflammatory cytokines in RA stimulate osteoprotegerin ligand (OPGL) expression on synoviocytes and T cells.
  • OPGL drives osteoclast formation and activation, resulting in osteoporosis and bone erosions in RA patients.

Purpose of the Study:

  • To review the mechanisms of bone disease in rheumatoid arthritis.
  • To discuss the role of osteoprotegerin ligand in RA-associated bone loss.
  • To highlight the potential of bone densitometry and novel therapies for managing rheumatoid bone disease.

Main Methods:

  • Review of recent studies on pro-inflammatory cytokines, osteoprotegerin ligand, and bone metabolism in rheumatoid arthritis.

Related Experiment Videos

  • Discussion of bone densitometry (dual-energy X-ray absorptiometry) as a monitoring tool.
  • Exploration of therapeutic strategies including anti-inflammatory agents and osteoprotegerin-based treatments.

    • Main Results:

    • Osteoprotegerin ligand (OPGL) is a key mediator of bone loss and erosions in rheumatoid arthritis.
    • Bone loss in early RA is rapid and correlates with inflammation and functional status.
    • Bone densitometry can serve as an outcome measure and prognostic indicator for functional disability.

    Conclusions:

    • Effective inflammation suppression and bone-active agents can mitigate RA-associated bone loss.
    • Osteoprotegerin (OPG), a decoy receptor for OPGL, shows promise in blocking bone disease without impacting inflammation in animal models.
    • Future biological agents targeting the OPGL pathway may offer effective prevention and treatment for rheumatoid bone disease.